IP Library › Granted Patent US 12,237,063
Granted Patent B2
US 12,237,063 · App. 17/736,825 · Granted Feb 25, 2025

Methods and devices for minimally burdensome blood glucose management for insulin-requiring diabetes

Inventor: Lane Desborough (Thousand Oaks, CA)
Assignee: Nudge BG, Inc.
G16H20/17A61M5/14248A61M5/1723G05B23/0272G16H40/40G16H40/67A61M2205/18A61M2205/3584A61M2205/502A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,237,063
App. No.
17/736,825
Granted
Feb 25, 2025
Kind
B2
Abstract

Some embodiments include burden-free insulin delivery systems and methods. In some embodiments, a method may include receiving previous insulin delivery data at a user device from an insulin pump; receiving estimated glucose data at the user device from a continuous glucose monitor; determining an insulin delivery amount based on the previous insulin delivery data and the estimated glucose data to bring the estimated glucose data closer to a target glucose value without using any user-specific behavioral data physically entered by a user through a user interface of the user device within a previous period of time, the previous period of time being less than six hours; and communicating the insulin delivery amount to the insulin pump.

Claims (25)

1. A method comprising:

receiving previous insulin delivery data at a user device from an insulin pump;

receiving estimated glucose data at the user device from a continuous glucose monitor;

determining an insulin delivery amount based on the previous insulin delivery data and the estimated glucose data to bring the estimated glucose data closer to a target glucose value without using user-specific physiological data that is physically entered by a user through a user interface of a device within a previous period of time, the previous period of time being more than 60 minutes and less than 6 hours; and

communicating the insulin delivery amount to the insulin pump.

2. The method according to claim 1 , wherein the previous insulin delivery data includes the amount of insulin delivered to the user over a period of time.

3. The method according to claim 1 , wherein the insulin delivery data is received from the insulin pump via Bluetooth.

4. The method according to claim 1 , wherein the estimated glucose data is received from the continuous glucose monitor via Bluetooth.

5. The method according to claim 1 , wherein the user-specific physiological data comprises data selected from the list consisting of one or more of a glucose value, an estimated glucose value, a ketone measurement, an insulin delivery trend, physical activity data, movement data, and exertion data.

6. The method according to claim 1 , wherein the period of time is between 2 and 15 minutes.

7. The method according to claim 1 , wherein the previous period of time comprises 3 hours.

8. The method according to claim 1 , wherein the previous period of time comprises 1 hour.

9. The method according to claim 1 , wherein the insulin delivery amount comprises an insulin correction to a basal insulin rate.

10. The method according to claim 1 , wherein the user device and the insulin pump comprise a single device.

11. A non-transitory computer-readable medium storing instructions that, when executed by a mobile computing device, cause the mobile computing device to:

receive previous insulin delivery data from an insulin pump;

receive estimated glucose data from a continuous glucose monitor;

determine an insulin delivery amount based on the previous insulin delivery data and the estimated glucose data to bring the estimated glucose data closer to a target glucose value without using user-specific data that is physically entered by a user through a user interface of the mobile device within the previous period of time, the previous period of time being more than 60 minutes and less than 6 hours; and

communicate the insulin delivery amount to the insulin pump.

12. The non-transitory computer-readable medium according to claim 11 , wherein the user-specific data comprises either user-specific behavioral data or user specific physiological data.

13. The non-transitory computer-readable medium according to claim 11 , wherein the user-specific data comprises data selected from the list consisting of one or more of a mealtime announcement, a meal carbohydrate content estimate, an exercise announcement, and a sleep announcement.

14. The non-transitory computer-readable medium according to claim 11 , wherein the user-specific data comprises data selected from the list consisting of one or more of a glucose value, an estimated glucose value, a ketone measurement, an insulin delivery trend, physical activity data, movement data, and exertion data.

15. The non-transitory computer-readable medium according to claim 11 , wherein the previous period of time comprises 3 hours.

16. The non-transitory computer-readable medium according to claim 11 , wherein the previous period of time comprises 1 hour.

17. The non-transitory computer-readable medium according to claim 11 , wherein the insulin delivery amount comprises an insulin correction to a basal insulin rate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2022
From: DESBOROUGH, LANE
To: NUDGE BG INC.
Reel/Frame 059818/0604 →
Continuity (4)
Continuation 17149611 · Jan 14, 2021
Provisional Application 62962179 · Jan 16, 2020
Provisional Application 62962178 · Jan 16, 2020
Related Publication 20220262479A1 · Aug 18, 2022
References Cited (20)
US 9878097B2 · Estes · 2018 [cited by applicant]
US 11101030B2 · Desborough · 2021 [cited by applicant]
US 11942202B2 · Desborough · 2024 [cited by examiner]
US 20080021666A1 · Goode, Jr. et al. · 2008 [cited by applicant]
US 20090006034A1 · Hayter et al. · 2009 [cited by applicant]
US 20110184267A1 · Duke et al. · 2011 [cited by applicant]
US 20120226259A1 · Yodfat et al. · 2012 [cited by applicant]
US 20170086756A1 · Harper et al. · 2017 [cited by applicant]
US 20170189614A1 · Mazlish et al. · 2017 [cited by applicant]
US 20170203036A1 · Mazlish et al. · 2017 [cited by applicant]
Invitation to Pay Additional Fees as issued in connection with International Patent Application No. PCT/US2021/013496, mailed Mar. 9, 2021, 2 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/149,598 dated Mar. 30, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion as issued in connection with International Patent Application No. PCT/US2021/013496, mailed May 13, 2021, 11 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/149,598 dated May 25, 2021, 9 pages. [cited by applicant]
International Preliminary Report on Patentability as issued in connection with International Patent Application No. PCT/US2021/013496, mailed Jul. 19, 2022, 7 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/403,518 dated Sep. 8, 2023, 18 pages. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 17/149,611 dated Dec. 15, 2023, 7 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/403,518 dated Dec. 20, 2023, 9 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/149,611 dated Jul. 18, 2024, 08 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/736,813 dated Aug. 8, 2024, 9 pages. [cited by applicant]